FACTORS AFFECTING THE ABSOLUTE BIOAVAILABILITY OF NIFEDIPINE

被引:124
作者
RASHID, TJ [1 ]
MARTIN, U [1 ]
CLARKE, H [1 ]
WALLER, DG [1 ]
RENWICK, AG [1 ]
GEORGE, CF [1 ]
机构
[1] UNIV SOUTHAMPTON,CLIN PHARMACOL GRP,SOUTHAMPTON SO16 7PX,HANTS,ENGLAND
关键词
NIFEDIPINE; ETHNIC DIFFERENCES; BIOFLAVONOIDS; GRAPEFRUIT JUICE; BIOAVAILABILITY; CYP3A;
D O I
10.1111/j.1365-2125.1995.tb04534.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Nifedipine was administered to eight volunteers (seven Caucasian, one East Asian of Chinese origin) as a single 10 mg capsule orally and as 2.5 mg intravenously. The pharmacokinetics were determined under fasting conditions and following 200 mi double strength grapefruit juice taken orally both 2 h before and at the time of dosing. 2 In a separate study, the pharmacokinetics of nifedipine were defined in eight South Asian volunteers (with both parents originating from the Indian subcontinent) following 10 mg nifedipine orally and 2.5 mg intravenously. 3 The administration of grapefruit juice did not alter the pharmacokinetics of intravenous nifedipine, but resulted in a significantly increased area under the plasma concentration-time curve (AUG) (191 +/- 59 c.f. 301 +/- 95 ng ml(-1) h, P < 0.05) and bioavailability (0.63 +/- 0.18 c.f: 0.86 +/- 0.15, P < 0.05) following oral nifedipine, The elimination half-life was unchanged by administration of grapefruit juice and there was no evidence of decreased formation of the nitropyridine first-pass metabolite. 4 The AUC of nifedipine after intravenous administration was significantly higher in South Asian subjects than in Caucasians (146 +/- 39 c.f. 74 +/- 18 ng ml(-1) h, P < 0.002). This was due to a lower systemic clearance in the South Asians which was 50% of that in the Caucasians. The half-life was markedly prolonged in South Asians (4.1 +/- 1.9 c.f: 1.7 +/- 0.5 h, P < 0.002). 5 The oral administration of nifedipine resulted in a significantly higher AUC of nifedipine in the South Asian compared with the Caucasian volunteers (402 +/- 198 c.f: 187 +/- 62 ng ml(-1) h, P < 0.05). However, the bioavailability was similar at 0.64, suggesting that reduced systemic clearance is the cause of the differences in AUCs observed with both routes of administration. Consistent with this, the elimination half-life was prolonged in the Asians (5.3 +/- 1.5 c.f: 2.6 +/- 1.1 h, P < 0.01). The AUC of the nitropyridine first-pass metabolite was similar in the two groups. 6 These data on the bioavailability and systemic clearance of nifedipine indicate that intestinal and hepatic CYP3A activities may be influenced independently by environmental and/or genetic factors.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 43 条
  • [1] ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE
    AHSAN, CH
    RENWICK, AG
    MACKLIN, B
    CHALLENOR, VF
    WALLER, DG
    GEORGE, CF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) : 399 - 403
  • [2] THE INFLUENCES OF DOSE AND ETHNIC-ORIGINS ON THE PHARMACOKINETICS OF NIFEDIPINE
    AHSAN, CH
    RENWICK, AG
    WALLER, DG
    CHALLENOR, VF
    GEORGE, CF
    AMANULLAH, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) : 329 - 338
  • [3] GRAPEFRUIT JUICE FELODIPINE INTERACTION - MECHANISM, PREDICTABILITY, AND EFFECT OF NARINGIN
    BAILEY, DG
    ARNOLD, JMO
    MUNOZ, C
    SPENCE, JD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) : 637 - 642
  • [4] INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE
    BAILEY, DG
    SPENCE, JD
    MUNOZ, C
    ARNOLD, JMO
    [J]. LANCET, 1991, 337 (8736) : 268 - 269
  • [5] BUENING MK, 1981, CANCER RES, V41, P67
  • [6] CASTANEDAHERNAN.G, 1992, J CLIN PHARMACOL, V32, P140
  • [7] THE TRANS-HEPATIC EXTRACTION OF NIFEDIPINE
    CHALLENOR, VF
    WALLER, DG
    RENWICK, AG
    GRUCHY, BS
    GEORGE, CF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (04) : 473 - 477
  • [8] INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE
    CHAYEN, R
    ROSENTHAL, T
    [J]. LANCET, 1991, 337 (8745) : 854 - 854
  • [9] DEFICIENT NIFEDIPINE OXIDATION - A RARE INHERITED TRAIT ASSOCIATED WITH CYSTIC-FIBROSIS KINDREDS
    DALY, AK
    SALH, BS
    BILTON, D
    ALLEN, J
    KNIGHT, AD
    WEBB, AK
    BRAGANZA, JM
    IDLE, JR
    [J]. PHARMACOGENETICS, 1992, 2 (01): : 19 - 24
  • [10] FOSTER TS, 1983, J CLIN PHARMACOL, V2, P161